Medpace Holdings Inc MEDP Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Feb 17, 2023 (filed on Feb 22, 2023)

Insider Name:

Ewald Stephen P

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Unit

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

1,000

Price:

--
Feb 17, 2023 (filed on Feb 22, 2023)

Insider Name:

Brady Kevin M.

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Unit

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

1,000

Price:

--
Feb 17, 2023 (filed on Feb 22, 2023)

Insider Name:

Burwig Susan E

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Unit

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

1,000

Price:

--
Feb 17, 2023 (filed on Feb 22, 2023)

Insider Name:

Geiger Jesse J

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Unit

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

1,000

Price:

--
Feb 17, 2023 (filed on Feb 22, 2023)

Insider Name:

Troendle August J.

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Unit

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

1,000

Price:

--
Jan 16, 2023 (filed on Jan 18, 2023)

Insider Name:

Gwadry-Sridhar Femida H.

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

573

Price:

--
Dec 09, 2022 (filed on Dec 13, 2022)

Insider Name:

Kraft Robert O.

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Unit

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

376

Price:

$205.77
Dec 09, 2022 (filed on Dec 13, 2022)

Insider Name:

McCarthy Cornelius P. III

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Unit

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

328

Price:

$205.77
Dec 09, 2022 (filed on Dec 13, 2022)

Insider Name:

Carley Brian T

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Unit

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

413

Price:

$205.77
Nov 16, 2022 (filed on Nov 17, 2022)

Insider Name:

Brady Kevin M.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-344

Price:

$227.09

Filings by filing date

Feb 17, 2023 (filed on Feb 22, 2023)

Insider Name:

Ewald Stephen P

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Unit

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

1,000

Price:

--
Feb 17, 2023 (filed on Feb 22, 2023)

Insider Name:

Brady Kevin M.

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Unit

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

1,000

Price:

--
Feb 17, 2023 (filed on Feb 22, 2023)

Insider Name:

Burwig Susan E

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Unit

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

1,000

Price:

--
Feb 17, 2023 (filed on Feb 22, 2023)

Insider Name:

Geiger Jesse J

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Unit

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

1,000

Price:

--
Feb 17, 2023 (filed on Feb 22, 2023)

Insider Name:

Troendle August J.

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Unit

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

1,000

Price:

--
Jan 16, 2023 (filed on Jan 18, 2023)

Insider Name:

Gwadry-Sridhar Femida H.

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

573

Price:

--
Dec 09, 2022 (filed on Dec 13, 2022)

Insider Name:

Kraft Robert O.

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Unit

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

376

Price:

$205.77
Dec 09, 2022 (filed on Dec 13, 2022)

Insider Name:

McCarthy Cornelius P. III

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Unit

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

328

Price:

$205.77
Dec 09, 2022 (filed on Dec 13, 2022)

Insider Name:

Carley Brian T

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Unit

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

413

Price:

$205.77
Nov 16, 2022 (filed on Nov 17, 2022)

Insider Name:

Brady Kevin M.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-344

Price:

$227.09

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	5375 Medpace Way CINCINNATI OH 45227-1543
Tel:	N/A
Website:	https://investor.medpace.com
IR:	See website

Key People

August J. Troendle Chairman of the Board, Chief Executive Officer	Jesse J. Geiger President, Chief Operating Officer - Laboratory Operations	Kevin M. Brady Chief Financial Officer, Treasurer
Susan E. Burwig Executive Vice President - Operations	Stephen P. Ewald General Counsel, Corporate Secretary

Business Overview

Medpace Holdings, Inc. is a global provider of clinical research-based drug and medical device development services. The Company is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company's drug development services focuses on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. It also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.

Financial Overview

For the fiscal year ended 31 December 2022, Medpace Holdings Inc revenues increased 28% to $1.46B. Net income applicable to common stockholders increased 35% to $245.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Miscellaneous (expense) increase from $563K to $3.2M (income), Amortization decrease of 34% to $3.4M (expense).

Employees:	5,200 as of Dec 31, 2022

Reporting Currency:	U.S. Dollars
Enterprise value:	$5,658M as of Dec 31, 2022
Annual revenue (TTM):	$1,460M as of Dec 31, 2022
EBITDA (TTM):	$301.04M as of Dec 31, 2022
Net annual income (TTM):	$245.21M as of Dec 31, 2022
Free cash flow (TTM):	$351.17M as of Dec 31, 2022
Net Debt Last Fiscal Year:	$21.74M as of Dec 31, 2022
Shares outstanding:	31,050,160 as of Feb 10, 2023
Index Membership:	S&P 400 Mid Cap
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization